Twelve sessions of therapy do not necessarily deliver the same treatment. A randomized OCD trial compared exposure and response prevention with stress-management training and found different symptom outcomes. For families choosing private care, the result challenges a familiar assumption: more support, attention, or a fuller schedule does not automatically mean more appropriate treatment.
Key findings
126: participants randomized, with 63 assigned to each treatment.
12: weekly sessions planned in each group.
24.87 to 12.49: mean OCD-severity scores from baseline to week 12 in the exposure-and-response-prevention group.
27.48 to 22.46: corresponding mean scores in the stress-management group.
The groups started at different mean severity levels. The study’s adjusted analysis supports its treatment comparison; subtracting these raw means alone is not a substitute for that analysis. [1]
Similar contact, different symptom trajectories
Source: Himle and colleagues, published Table 2. These are group means, not the experience of every participant or a long-term recovery rate. [1]
| Assessment | Exposure and response prevention | Stress management |
|---|---|---|
| Baseline | 24.87 | 27.48 |
| Week 6 | 18.54 | 24.30 |
| Week 12 | 12.49 | 22.46 |
The child or adult Yale-Brown Obsessive Compulsive Scale was used according to age. Lower scores indicate lower symptom severity. The numerical comparison should retain the instrument and observation period, not become a general claim that a particular clinic achieves these results. [1]
What the trial actually tested
The study compared an OCD-specific intervention with an active stress-management treatment, rather than with no contact. Participants included adolescents ages 12 to 18 and adults ages 24 to 46. It therefore asked whether treatment content mattered beyond attention and a structured program.
It did not compare residential and outpatient care, expensive and inexpensive clinics, or treatment outcomes by wealth. Its implication for families is a purchasing question: which part of the proposed program treats OCD, and what evidence supports that part?
Supportive activities may still have a role. The result does not establish that relaxation or stress management is useless in every setting. It distinguishes a supportive or adjunctive role from a claim of equivalent effectiveness against the core disorder in the studied population.
Response is not the same as remission
The paper separates full response, partial response, and remission. Its abstract’s rounded response figures combine full and partial response. That makes the definition essential when quoting a success percentage. A large number can mislead when the threshold behind it disappears. [1]
Response means a specified improvement from baseline. Remission means meeting a low-symptom threshold at a particular assessment. Neither automatically establishes that improvement lasted for a year or that every aspect of functioning recovered. A person may benefit substantially and still need further care.
Families comparing programs should ask what success means in each report. Attendance, satisfaction, improvement on a symptom scale, and sustained remission are different claims. They need different evidence and should not be compared as though they describe the same endpoint.
A separate population signal among young adults
England’s Adult Psychiatric Morbidity Survey reported survey-assessed OCD among ages 16 to 24 at 1.5% in 2000 and 5.7% in 2023/24. The published 95% confidence intervals were 0.8% to 2.9% and 3.3% to 9.6%, respectively. These are population-survey estimates, not counts of new clinical diagnoses. [2]
The wide interval around the latest estimate remains important when reusing the figure. Source: APMS. [2]
The survey and trial answer different questions. One estimates prevalence; the other compares treatments in selected participants. Combining them to calculate how many young people would recover under a particular program would go beyond the evidence.
Why precision matters for high-achieving families
Meticulousness, ambition, or a demanding job should not be used to diagnose someone. Nor should academic or professional success be used to dismiss distress. The clinical question concerns the nature and impact of the difficulties, not a stereotype about achievement.
Before comparing packages, ask about OCD-specific expertise, assessment, and treatment delivery. A program should explain what is directed at OCD and what addresses supportive or co-occurring needs. The number of available therapies is less informative than the rationale for the proposed combination.
Parents and partners can support an appropriate assessment and help clarify practical needs. That does not mean conducting exposure exercises independently or pressuring someone to disclose distressing thoughts publicly. This article is not a self-treatment protocol. Clinical planning should involve appropriately qualified professionals.
For internationally mobile patients, the same specificity should extend to follow-up. The next clinician needs an account of the intervention, response, difficulties, and continuing goals. A handover should not reduce a detailed course of treatment to the statement that therapy was completed.
What a useful outcome report should show
An OCD report should identify the measure, baseline severity, response and remission definitions, assessment timing, and number followed. It should distinguish all entrants from completers and survey respondents. Co-occurring difficulties and subsequent treatment also matter when interpreting results.
Condition-specific measures can be complemented by functioning, quality of life, and patient-defined goals. These additions should not replace the core evidence with a vague statement that someone felt better. A program serving complex patients may need several measures rather than a single favorable score.
For someone returning to leadership or family responsibilities, the question is whether gains persist in ordinary circumstances. A favorable assessment at the end of a structured stay is useful but incomplete. Later follow-up needs its own denominator and should make missing information visible.
The treatment comparison should also be realistic about differences between patients. Age, starting severity, prior treatment, and co-occurring conditions can change how relevant a study is to an individual. A family should ask how the proposed plan relates to the studied intervention rather than assume that a familiar therapy name guarantees identical delivery.
Ask what happens between the scores
A symptom score is most useful when it is connected to a clear treatment history. What intervention was delivered, over how many sessions, and with what participation? Were there changes in medication or other care? Without that context, a before-and-after number can describe improvement while leaving the practical explanation unclear.
The same issue arises when a program advertises several forms of therapy together. Evidence for one intervention does not automatically validate the entire package. Families can ask which elements have condition-specific support, which address other needs, and how the clinician will judge whether the combination is helping. That is a request for clarity, not a demand that every supportive activity have an identical research history.
Follow-up should also preserve the difference between improvement and absence of symptoms. Someone may have made a meaningful gain while continuing to need treatment. Describing that outcome accurately is more useful than forcing it into a simple success-or-failure label. The response and remission definitions in the trial illustrate why the threshold should remain visible.
For a person with substantial family or professional responsibilities, the account of progress should include the activities they value. It should not assume that the fastest return to a full schedule is always the best result. A treatment plan can recognize both symptom change and sustainable functioning without promising enhanced performance or a permanent cure.
These questions make the report actionable without turning it into self-directed treatment instructions. The purpose is to help readers evaluate claims and discuss appropriate care with qualified clinicians. It is not to reproduce exposure exercises or select a treatment solely from the most favorable figure in a chart.
What these numbers cannot tell us
The trial does not establish results for a particular clinic or a wealthy population. The survey does not explain why prevalence changed. Neither supports a causal claim about ambition, social media, or family income. The figures should remain attached to their original populations and periods.
A separate 2024 German comparison of metacognitive therapy and ERP has an indexed corrigendum. It is retained as a research-development reference, not used here to rank treatments or quote corrected effect estimates. Later follow-up and corrected publications matter when evaluating a breakthrough headline. [3]
The bottom line
The trial challenges the idea that more elaborate support necessarily provides more relevant care. For OCD, treatment content matters. A quiet setting and generous attention cannot independently establish effectiveness. The question for every provider, including THE BALANCE, is what the clinical plan is intended to do and what evidence shows it did.
For journalists
Key comparison: two groups assigned 12 sessions showed different mean OCD-severity trajectories over 12 weeks.
Important caveat: the trial was not a comparison of private clinics, prices, or residential settings. Response and remission must not be treated as synonyms.
Suggested attribution: THE BALANCE analysis of published OCD treatment and population-survey evidence.
Methodology and sources
The trial chart reproduces published means, not a reanalysis of participant records. The population chart preserves age limits and confidence intervals. No new response denominator, private-provider success rate, or wealth-specific estimate is calculated. The source correction is identified separately from the main trial.
- Himle and colleagues. ERP versus stress-management training for adolescents and adults with OCD. Behaviour Research and Therapy, 2024;172:104458. DOI: 10.1016/j.brat.2023.104458.
- NHS England. APMS 2023/24, common mental health conditions chapter.
- Exner and colleagues. Metacognitive therapy versus ERP, 2024. Indexed corrigendum: 10.1016/j.janxdis.2024.102946.
